

Nemera to acquire Copernicus to boost parenteral product portfolio and small series capabilities

PRESS RELEASE
La Verpillière, France
27th October 2020

“As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy.

We are the utmost holistic partner and help our customers succeed in the sprint to market. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards.

Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.”

Marc Hämel, CEO

Nemera in figures:

- **4 plants** in Europe and USA
- **Insight Innovation Center** with offices in Europe and the US
- Over:**
- **2,400 employees**
- **30,000 sq. meters** of manufacturing clean rooms
- **150 engineers and experts** in our Insight Innovation Center

Document not legally binding
 Nemera ©2020

This acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters our small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands our overall proprietary product portfolio. Copernicus’ fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large scale manufacturing capabilities. Furthermore, Copernicus’ marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition we establish an operations footprint in Eastern Europe. In order to accompany Copernicus’ solid forecasted growth we will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, *“This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.*

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.



About Nemera

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera's vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients' health. Nemera's Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, our Insight Innovation Center helps customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first. For more information, visit www.nemera.net.